Assembly Biosciences announced positive interim Phase 1a results for ABI-1179, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate for recurrent genital herpes. The study in healthy participants showed ABI-1179 was well-tolerated with a favorable safety profile.
ABI-1179 demonstrated a half-life of approximately four days and high exposure across the dose range evaluated, exceeding Assembly Bio’s targets for a once-weekly oral dosing profile. At all doses, including the lowest 50 mg dose, ABI-1179 exceeded target plasma concentrations for antiviral activity.
Based on these data, Assembly Bio plans to move ABI-1179 directly into the Phase 1b portion of the study in participants with recurrent genital herpes. This Phase 1b study will run concurrently with the ongoing Phase 1b evaluation of ABI-5366, with interim data for both candidates anticipated in fall 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.